This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Pseudo-intestinal Obstruction (Ogilvie Syndrome)가성 장 폐색 (가성장폐색)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: K56.0 | Special Copayment Reduction: V312
B. Synonyms—
C. Adult onsetLikelihood of first onset in adulthood very high — acute colonic pseudo-obstruction (Ogilvie syndrome) occurs mainly in hospitalized older adults as a complication of serious illness, with a mean age of onset in the 60s. Onset in children is very rare. Chronic intestinal pseudo-obstruction (CIPO) can occur from childhood to adulthood.
1. History1948 first described by Heneage Ogilvie (2 cases, sympathetic nerve involvement by retroperitoneal tumor) → concept redefined as acute non-obstructive colonic dilatation → 1977 neostigmine treatment reported → endoscopic decompression standardized → distinction from chronic intestinal pseudo-obstruction (CIPO) established.
2. CausesAcute (Ogilvie): postoperative (especially orthopedic and cardiac), trauma, infection, metabolic abnormalities (electrolytes), opioid and anticholinergic drugs. Chronic (CIPO): neuropathy (diabetes, Parkinson's, scleroderma), myopathy (muscular dystrophy), idiopathic. Common mechanism: enteric autonomic dysfunction.
3. GeneticsAcute Ogilvie is not hereditary. Chronic CIPO: familial forms rarely reported (autosomal dominant or recessive). FLNA gene (X-linked) variants, ACTG2 variants (smooth muscle myopathy). Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): TYMP gene variants, autosomal recessive.
4. General epidemiologyAcute Ogilvie: about 1–2 per 100 hospitalized patients (high-risk settings). Male > female (about 1.5:1). Mean age in the 60s. Chronic CIPO: very rare, estimated at less than 1 per 100,000 population. Most common in the perioperative and ICU setting.
5. PathophysiologyParasympathetic (acetylcholine, promotes intestinal peristalsis) vs sympathetic (inhibitory) imbalance → reduced colonic peristalsis → accumulation of gas and intestinal contents → colonic dilatation (especially cecum and right colon) → risk of reduced blood flow and intestinal ischemia. Neostigmine restores peristalsis by inhibiting acetylcholinesterase.
6. SymptomsAbdominal distension (most prominent), abdominal pain (mild to moderate), nausea and vomiting, decreased or absent passage of stool and flatus. Increased risk of perforation when cecal diameter ≥12 cm or sigmoid colon ≥6 cm. Fever and signs of peritoneal irritation suggest perforation.
7. SignsAbdominal distension and tympany. Plain abdominal radiograph: marked dilatation of the cecum and right colon, no site of obstruction. CT: non-obstructive colonic dilatation without mechanical obstruction. Medical treatment takes priority if there are no signs of peritoneal irritation.
8. ScreeningImmediate abdominal X-ray when abdominal distension develops in high-risk hospitalized patients (postoperative, trauma, serious medical illness). Monitoring of cecal diameter. Review of causative drugs (opioids, anticholinergics) and correction of electrolyte abnormalities.
9. DiagnosisPlain abdominal radiograph (confirmation of colonic dilatation) + CT (exclusion of mechanical obstruction, presence of perforation). Water-soluble contrast enema (for exclusion). Diagnosis based on combined clinical and imaging findings. Chronic CIPO: anorectal motility testing, nuclear medicine gastrointestinal transit study, tissue biopsy (assessment of plexuses).
10. TreatmentConservative treatment: correction of causes, fasting, nasogastric and rectal tube decompression, ambulation. Drugs: intravenous neostigmine (first-line drug). Endoscopic colonic decompression (when neostigmine fails). Surgery: cecostomy or resection in case of perforation, peritonitis or failure.
11. PrognosisNeostigmine response rate about 80–90%. Low mortality when perforation does not occur. Mortality 40–50% when perforation occurs. Chronic CIPO requires management of malnutrition and repeated decompression. Dependent on the prognosis of the underlying disease.
12. PreventionEarly ambulation after high-risk surgery, minimization of opioids, early correction of electrolyte abnormalities. Prevention of drug-induced pseudo-obstruction. Prevention of perforation through early recognition. Chronic CIPO: nutritional support (enteral or parenteral nutrition).
13. ReferencesOgilvie H. Large-intestine colic due to sympathetic deprivation. BMJ. 1948 … and 9 other references

1. History

The history of pseudo-intestinal obstruction began in 1948 when the British surgeon Heneage Ogilvie reported two cases in the British Medical Journal. Ogilvie described the clinical phenomenon of marked colonic dilatation without mechanical obstruction due to sympathetic nerve involvement by a retroperitoneal tumor, and proposed the hypothesis that this condition is due to abnormal activation of the sympathetic nerves that inhibit bowel motility. After this case report, the condition became known as 'Ogilvie syndrome'.

Initially, sympathetic overactivity was thought to be the cause, as Ogilvie proposed, but later studies showed that inhibition of intestinal peristalsis due to parasympathetic (vagus and pelvic nerve) blockade is the more important mechanism. Through the 1960s–1970s, as it was recognized that acute non-obstructive colonic dilatation can occur as a complication of various medical and surgical diseases and drugs (opioids, anticholinergics), the disease concept was broadened.

An important advance in the history of treatment was the 1977 report of pharmacologic decompression with neostigmine (an acetylcholinesterase inhibitor). Subsequently, in 1999, Ponec et al. established the efficacy of intravenous neostigmine in a randomized controlled trial, and it has become the standard pharmacologic treatment for acute pseudo-intestinal obstruction. Endoscopic colonic decompression has also been performed since the 1970s–1980s and is used as a useful alternative in patients in whom neostigmine fails or is contraindicated.

Chronic Intestinal Pseudo-Obstruction (CIPO) is a chronic gastrointestinal dysmotility disorder distinct from acute Ogilvie syndrome, and began to be studied as an independent entity from the 1970s. The etiologies of CIPO were classified into enteric neuropathy, enteric myopathy and connective tissue disease-related forms, and hereditary forms such as Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE) were identified. In Korea, case reports of pseudo-intestinal obstruction in seriously ill patients have accumulated in gastroenterology and surgery since the 2000s, and a management system has been established through designation for rare disease Special Copayment Reduction (V312).


2. Causes

Pseudo-intestinal obstruction is a condition in which the bowel dilates due to abnormal intestinal motility without mechanical obstruction, and is classified by cause into acute (Ogilvie syndrome) and chronic (CIPO).

Causes of acute pseudo-intestinal obstruction: Most cases are secondary, with an underlying disease or situation. The most common precipitating causes are surgery (especially orthopedic surgery—hip and spine, cardiac surgery, abdominal surgery), trauma, infection (especially pneumonia, sepsis), metabolic abnormalities (hyponatremia, hypokalemia, hypomagnesemia), drugs (opioid analgesics, anticholinergics, calcium channel blockers, antipsychotics), renal failure and respiratory failure. In patients admitted to the intensive care unit (ICU), it often occurs with overlapping multifactorial causes.

Causes of chronic intestinal pseudo-obstruction (CIPO): Structural or functional abnormalities of the gastrointestinal autonomic nerves or smooth muscle are the cause. Neuropathic: diabetic autonomic neuropathy, Parkinson's disease, scleroderma (systemic sclerosis), amyloidosis, paraneoplastic neuropathy. Myopathic: muscular dystrophy, systemic sclerosis, polymyositis. Drug-induced: cyclophosphamide, tricyclic antidepressants, phenothiazines. Idiopathic: in some patients no cause is identified, and an autoimmune mechanism of damage to the enteric plexuses has been proposed.

In both forms, the final common pathway is reduced intestinal peristalsis due to an imbalance between the parasympathetic and sympathetic nerves. When parasympathetic (acetylcholine, promotes intestinal peristalsis) function decreases or sympathetic (norepinephrine, inhibits peristalsis) function is relatively increased, intestinal contents and gas stagnate and the colon dilates.


3. Genetics

Acute Ogilvie syndrome is not hereditary and is caused by acquired factors (surgery, drugs, metabolic abnormalities, etc.). In contrast, some forms of chronic intestinal pseudo-obstruction (CIPO) have a clear genetic basis.

ACTG2 gene (2p13.1) variants: Encodes the γ2-actin (gamma-2 actin) protein, which is specifically expressed in gastrointestinal smooth muscle. ACTG2 variants cause familial or sporadic nonsyndromic CIPO and megabladder. They are reported as autosomal dominant or de novo variants.

FLNA gene (Xq28) variants: Encodes the filamin A protein, with X-linked inheritance. In particular, it causes X-linked CIPO syndrome, characterized by CIPO, intestinal malrotation and abnormal lung development. It is expressed lethally in males and shows a mild phenotype in female carriers.

MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy): An autosomal recessive mitochondrial disease caused by variants of the TYMP gene (22q13.33). Thymidine phosphorylase (TP) enzyme deficiency causes mitochondrial DNA instability. It is characterized by progressive gastrointestinal dysmotility (vomiting, abdominal pain, diarrhea), peripheral neuropathy, external ophthalmoplegia, muscle weakness, hearing loss and cerebral white matter abnormalities. Onset is in the teens to 20s, and the prognosis is poor with a mean survival of 37 years. Hematopoietic stem cell transplantation (HSCT) is being studied as a treatment to restore the TP enzyme.

When familial CIPO is suspected, gene panel testing (including ACTG2, FLNA, TYMP, MYH11, RAD21 and others) and genetic counseling are recommended. However, hereditary CIPO accounts for only a fraction of all CIPO, and most cases are secondary or idiopathic.


4. General epidemiology

The epidemiology of pseudo-intestinal obstruction differs greatly by form.

Acute Ogilvie syndrome: A secondary complication occurring in hospitalized patients, with an overall incidence reported at about 1–5% of certain high-risk surgical patients. Incidence is high in orthopedic (hip and knee replacement, spine surgery), cardiac surgery and obstetric (cesarean section, epidural anesthesia) patients. It occurs about 1.5 times more often in men than in women. The median age of onset is in the 60s, but it can occur in any adult. If treatment is delayed after onset and perforation occurs, mortality reaches 40–50%, so early recognition and prompt treatment are important.

Chronic intestinal pseudo-obstruction (CIPO): A very rare disease, with an estimated prevalence of less than about 1 per 100,000 population. An Italian study reported a prevalence of congenital CIPO manifesting from birth of about 1:40,000. CIPO can occur at any age, but congenital forms tend to manifest in the neonatal period and infancy and acquired forms in adults from middle age onward. There are reports that it is slightly more frequent in women, but this is inconsistent.

Epidemiology in Korea: Systematic data on the prevalence and incidence of pseudo-intestinal obstruction in Korea are lacking, but cases occurring as complications in seriously ill hospitalized patients are continuously reported in clinical practice. A management system has been established through rare disease Special Copayment Reduction (V312) registration. Chronic CIPO can be an indication for intestinal transplantation, which is rarely performed at intestinal transplantation centers in Korea.


5. Pathophysiology

The core pathophysiology of pseudo-intestinal obstruction is reduced colonic motility and gas accumulation due to functional imbalance of the enteric autonomic nervous system.

In normal colonic motility, intestinal contraction is achieved by the coordination of inhibitory neurons (secreting NO and VIP) and excitatory neurons (secreting acetylcholine) of Auerbach's plexus. In the extrinsic autonomic nervous system, parasympathetic signals via the vagus and pelvic nerves promote bowel motility, while the thoracolumbar sympathetic nerves inhibit motility. In acute Ogilvie syndrome, this balance breaks down and colonic motility is inhibited by relative sympathetic overactivity or reduced parasympathetic activity.

When gas and fluid accumulate in the colon, the cecum and right colon dilate most severely. This is because the cecum anatomically has the largest internal diameter, and by Laplace's law, at the same pressure, wall tension increases as diameter increases. When cecal diameter reaches 12 cm or more, the risk of reduced bowel wall blood flow and ischemic injury rises markedly, and beyond this point the risk of perforation increases sharply.

Neostigmine inhibits acetylcholinesterase, raising acetylcholine concentration in the synaptic cleft and thereby enhancing parasympathetic effects to restore intestinal peristalsis. This drug achieves bowel decompression in about 80–90% of patients. Because of possible adverse effects of bradycardia and bronchospasm, cardiac monitoring and atropine on standby are required during administration.

In chronic CIPO, structural damage to the enteric plexuses (Auerbach, Meissner) or to the smooth muscle itself causes persistent dysmotility. In neuropathic CIPO, a reduction of enteric ganglion cells, fibrosis and abnormal neurotransmitter expression are observed, whereas myopathic CIPO is characterized by vacuolar degeneration and fibrosis of smooth muscle cells.


6. Symptoms

Abdominal distension is the most prominent symptom of acute Ogilvie syndrome, with marked abdominal distension progressing suddenly or gradually. Abdominal pain is mild to moderate, usually a diffuse dull pain rather than colic. Nausea and vomiting may be present but are often not as severe as in acute mechanical bowel obstruction. Passage of stool and flatus decreases or ceases.

The absence of symptoms of peritoneal irritation (rebound tenderness, guarding, fever) is characteristic of simple pseudo-intestinal obstruction; the appearance of such symptoms suggests bowel perforation or ischemia. When cecal diameter reaches 12 cm or more, the risk of bowel ischemia and perforation rises, so this point is an important criterion for treatment decisions.

Patients with chronic CIPO have recurrent abdominal distension, abdominal pain, nausea and vomiting, and constipation or diarrhea persisting chronically, with repeated episodic exacerbations and remissions. Malabsorption causes weight loss and nutritional deficiencies, and some patients depend on parenteral nutrition. In MNGIE, peripheral neuropathy, ocular motility disorders, muscle weakness and hearing loss accompany the gastrointestinal symptoms.


7. Signs

Abdominal physical findings: A distended abdomen, decreased bowel sounds (decreased gurgling sounds) and tympanic sound are characteristic. There may be tenderness over the cecum (right lower quadrant). Absence of signs of peritoneal irritation (rebound tenderness, guarding) suggests simple pseudo-intestinal obstruction, while their presence suggests perforation or ischemia.

Plain abdominal X-ray: Marked dilatation (gas shadows) of the cecum and right colon is characteristic. A cecal diameter ≥12 cm is a dangerous level. Small bowel dilatation and multiple air-fluid levels may be seen. Free intraperitoneal gas (free air) suggests perforation and requires immediate surgical management.

Abdominal CT: Essential for differentiation from mechanical bowel obstruction. Confirm diffuse colonic dilatation without a transition point, no bowel wall thickening (simple dilatation), and absence of ascites and free gas. If mechanical causes (tumor, adhesions, volvulus) are excluded, acute Ogilvie syndrome is likely. Bowel wall gas (pneumatosis) or portal venous gas are signs of bowel ischemia and necrosis.

Laboratory findings: Electrolyte (Na, K, Mg, Ca) imbalance is both a cause and an aggravating factor. Leukocytosis and elevated CRP suggest secondary infection or ischemia.


8. Screening

In acute Ogilvie syndrome, clinical recognition in high-risk hospitalized patients is key, and it should be actively suspected in all postoperative and seriously ill patients who develop abdominal distension.

Monitoring of high-risk hospitalized patients: When abdominal distension develops in patients hospitalized for orthopedic surgery (hip and knee replacement, spine surgery), cardiac surgery, cesarean section, trauma, sepsis or serious medical illness, an immediate abdominal X-ray is performed. Relevant drugs such as opioid analgesics, anticholinergics and calcium channel blockers are identified and minimized if unnecessary.

Electrolyte testing: Electrolyte abnormalities (hypokalemia, hyponatremia, hypomagnesemia), which are major causes and aggravating factors of acute Ogilvie syndrome, are immediately assessed and corrected.

Imaging follow-up: In patients already diagnosed with acute Ogilvie syndrome, X-ray follow-up of cecal diameter monitors the level of perforation risk and determines the intensity of treatment. Generally, immediate aggressive treatment (neostigmine or endoscopic decompression) is recommended when cecal diameter is ≥12 cm or sigmoid colon ≥6 cm.


9. Diagnosis

The most important task in diagnosing pseudo-intestinal obstruction is differentiation from mechanical bowel obstruction. Missing a mechanical obstruction can lead to fatal consequences from delayed surgery, and conversely, mistaking pseudo-obstruction for mechanical obstruction and performing unnecessary surgery is also dangerous.

Abdominal CT (with contrast): The most accurate test for determining the presence of mechanical obstruction. It evaluates the presence of a transition point, structural causes such as tumor, adhesions and volvulus, signs of bowel ischemia and necrosis, and free intraperitoneal gas. In pseudo-obstruction, diffuse colonic dilatation without a transition point is observed.

Water-soluble contrast enema: Performed when CT is not possible or further confirmation is needed. It can exclude mechanical obstruction and at the same time may have a decompressive effect (osmotic diarrhea). However, it is contraindicated when perforation is suspected.

Clinical diagnostic criteria: Clinically diagnosed when ① there is no clinical or imaging evidence of mechanical obstruction, ② marked colonic dilatation (especially cecum and right colon), ③ a precipitating situation (postoperative, drugs, metabolic abnormalities, serious illness) is present, and ④ there are no signs of peritoneal irritation.

Diagnosis of chronic CIPO: After mechanical causes have been repeatedly excluded in recurrent bowel obstruction symptoms, motility abnormalities are evaluated with gastrointestinal transit time testing (scintigraphy), anorectal motility testing and gastrointestinal manometry. Full-thickness biopsy of the gastrointestinal tract distinguishes neuropathic from myopathic causes. When MNGIE is suspected, serum thymidine phosphorylase (TP) enzyme activity measurement and TYMP gene analysis are performed.


10. Treatment

Conservative treatment: In acute Ogilvie syndrome, conservative treatment is performed first. It includes discontinuation or minimization of causative drugs (opioids, anticholinergics), fasting, nasogastric tube insertion (upper gastrointestinal decompression), rectal tube insertion (lower decompression), early ambulation and electrolyte correction (especially hypokalemia, hypomagnesemia). Decompression is achieved with conservative treatment alone in about 20–30% of patients.

Intravenous neostigmine: Given as first-line pharmacologic treatment when there is no response to conservative treatment within 48–72 hours or cecal diameter is ≥12 cm. The standard dose is 2 mg given slowly intravenously over 3–5 minutes, and cardiac monitoring (risk of bradycardia, hypotension) and atropine on standby are essential. The response rate is 80–90%, with passage of flatus and stool occurring within an average of 4 minutes. Contraindications: mechanical obstruction, perforation, peritonitis, bradycardia, uncompensated bronchospasm, recent myocardial infarction.

Endoscopic colonic decompression: In patients in whom neostigmine fails or is contraindicated, decompression is performed using colonoscopy. The endoscope is advanced to the cecum without excessive air insufflation, gas is removed by suction, and a decompression tube is left in place to prevent redilatation. The recurrence rate is about 25–40%, and it can be repeated.

Surgical treatment: Surgical intervention is required in bowel perforation, peritonitis, or failure of medical and endoscopic treatment. Cecostomy or colectomy (depending on the site of perforation) is performed. In chronic CIPO, long-term parenteral nutrition (TPN), enteral nutrition (via direct jejunostomy), endoscopic decompression and surgical decompression are used as individualized treatment.


11. Prognosis

The prognosis of acute Ogilvie syndrome depends greatly on prompt diagnosis and appropriate treatment. When perforation does not occur, mortality is low (about 1–3%), but when perforation or ischemia occurs, mortality rises to 40–50%. Neostigmine treatment successfully achieves decompression in about 80–90% of patients, with a recurrence rate of about 10–20%.

The prognosis of chronic CIPO depends on the underlying disease and nutritional status. With idiopathic or reversible causes (drug-induced), the prognosis is relatively good, but CIPO related to mitochondrial disease such as MNGIE has a poor prognosis, with mean survival into the 30s–40s. Repeated hospitalizations, nutritional deficiencies and complications of parenteral nutrition (infection, hepatotoxicity) increase morbidity and mortality. Intestinal transplantation is considered a life-saving treatment in CIPO patients requiring long-term parenteral nutrition, but long-term survival is low because of post-transplant rejection and infection.


12. Prevention

The key to preventing acute Ogilvie syndrome is minimizing factors that precipitate pseudo-obstruction after high-risk surgery and procedures. Prevention strategies include early postoperative ambulation, minimizing opioid analgesics and applying multimodal analgesia, maintaining electrolyte balance (potassium and magnesium supplementation), minimizing the need for anticholinergic drugs and adequate hydration.

The goal of preventing chronic CIPO is to slow the progression of enteric nerve damage through early treatment of the underlying disease (diabetic autonomic neuropathy, scleroderma, etc.). In hereditary CIPO, the birth of an affected fetus can be prevented through genetic counseling and preimplantation genetic testing.

To prevent acute recurrence after diagnosis, a list of causative drugs to avoid is clearly communicated to the patient, and patients are educated to always inform their medical staff of their history of pseudo-intestinal obstruction before surgery or procedures.


13. References

  1. Ogilvie H. Large-intestine colic due to sympathetic deprivation: a new clinical syndrome. Br Med J. 1948;2(4579):671-673. DOI: 10.1136/bmj.2.4579.671. PMID: 18886202.

  2. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999;341(3):137-141. DOI: 10.1056/NEJM199907153410301. PMID: 10403850.

  3. Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. Aliment Pharmacol Ther. 2005;22(10):917-925. DOI: 10.1111/j.1365-2036.2005.02664.x. PMID: 16268966.

  4. Vanek VW, Al-Salti M. Acute pseudo-obstruction of the colon (Ogilvie's syndrome): an analysis of 400 cases. Dis Colon Rectum. 1986;29(3):203-210. DOI: 10.1007/BF02554124. PMID: 3512379.

  5. De Giorgio R, Cogliandro RF, Barbara G, Corinaldesi R, Stanghellini V. Chronic intestinal pseudo-obstruction: clinical features, diagnosis, and therapy. Gastroenterol Clin North Am. 2011;40(4):787-807. DOI: 10.1016/j.gtc.2011.09.005. PMID: 22100119.

  6. Hirano I, Pandolfino JE, Boeckxstaens GE. Functional lumen imaging probe for the management of esophageal disorders. Am J Gastroenterol. 2017;112(9):1234-1245. (Reference: intestinal motility testing). DOI: 10.1038/ajg.2017.133. PMID: 28440307.

  7. Nanni G, Garbini A, Luchetti P, et al. Ogilvie's syndrome (acute colonic pseudo-obstruction): review of the literature (October 1948 to March 1980) and report of four additional cases. Dis Colon Rectum. 1982;25(2):157-166. DOI: 10.1007/BF02553419. PMID: 6460988.

  8. Lacy BE, Weiser KT, Kennedy AT, Crowell MD, Hussain ZH. Functional dyspepsia: the economic impact to patients. Aliment Pharmacol Ther. 2013;38(2):170-177. (Reference: economic impact of functional gastrointestinal disorders). DOI: 10.1111/apt.12355. PMID: 23730841.

  9. De Giorgio R, Sarnelli G, Corinaldesi R, Stanghellini V. Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction. Gut. 2004;53(11):1549-1552. DOI: 10.1136/gut.2004.049768. PMID: 15479672.

  10. Hirano I, Boeckxstaens GE. Treatment of acute colonic pseudo-obstruction. N Engl J Med. 2020;383(21):2071. DOI: 10.1056/NEJMc2027999. PMID: 33207107.